Muscle-invasive and Metastatic Bladder Cancer

This course compiles the most recent clinical guidelines edited by the EAU in relation to Muscle-invasive and Metastatic Bladder Cancer. Muscle-invasive and Metastatic Bladder Cancer course is divided in 2 learning units. Each Learning Unit consists of multiple choice questions that you can answer by navigating to the corresponding chapter of the Muscle-invasive and Metastatic Bladder Cancer guideline. The questions are offered for self-assessment of your knowledge of the EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.

Bladder cancer (BC) is the 7th most commonly diagnosed cancer in males. Incidence and mortality rates vary across countries. For about 35% of patients, bladder cancer is either muscle-invasive or metastatic at disease presentation. Non-muscle invasive disease can progress to become muscle-invasive bladder cancer later on in the disease course.

The standard treatment for patients with urothelial muscle invasive bladder cancer (MIBC) is radical cystectomy (RC). However, RC only provides 5-year survival in about 50% of patients. Review the Guidelines on disease management in this sheet.

This Cheat Sheet discusses various strategies for urinary diversion following radical cystectomy, highlighting the use of the ileum, colon, and appendix. The document emphasizes the importance of the 'Fast tract'/ERAS protocol in improving post-operative outcomes and discusses the management of locally-advanced disease, including palliative treatments and bladder-sparing options like transurethral resection, external beam radiotherapy, chemotherapy, and trimodality bladder-preserving treatment.

This document covers adjuvant chemotherapy and immunotherapy roles, recent advancements in metastatic UC treatment, and combination therapy standards like EV + Pembrolizumab. Key points include eligibility criteria, survival outcomes, and managing immune-related adverse effects.